Survodutide
In clinical trialsAlso known as: BI 456906
Category: Weight & metabolic
Sold as:
Ameano Peptides: Survodutide
Nexaph: Survodutide
Investigational dual glucagon and GLP-1 receptor agonist from Boehringer Ingelheim, studied for weight loss and fatty liver disease.
What it's used for
- Obesity (investigational)
- Fatty liver disease (MASH) (investigational)
Dosing
- Typical dose
- Trials escalated weekly doses over about 16 to 20 weeks up to 3.6 to 6 mg weekly. No approved dose exists.
- How often
- Once weekly
- Route
- Subcutaneous injection
- Cycle length
- Trial durations were 46 weeks or longer
Build a dosing plan for Survodutide →
How to reconstitute and measure a dose → · About bacteriostatic water →
Possible side effects
- Nausea, vomiting, diarrhea, which were more common than with GLP-1 only drugs
- Increased heart rate
Important: Not approved. Titrate slowly. GI side effects led many trial participants to stop.